mRNA Cancer Vaccines and Therapeutics refer to a class of medical treatments and preventive measures that utilize messenger RNA (mRNA) technology to stimulate an immune response specifically targeting cancer cells. Unlike traditional cancer therapies, which often involve radiation, chemotherapy, or surgery, mRNA cancer vaccines work by delivering synthetic mRNA sequences into the body. These sequences instruct cells to produce antigens associated with cancer, which then trigger the immune system to recognize and destroy malignant cells. The non-integrative and transient nature of mRNA ensures high safety, while recent advancements in lipid nanoparticle (LNP) delivery systems have significantly enhanced the efficacy and precision of these vaccines.
Market Size
The global mRNA Cancer Vaccines and Therapeutics market was valued at USD 2.85 billion in 2024 and is projected to reach USD 18.72 billion by 2032, growing at a CAGR of 26.5% during the forecast period.
This exponential growth reflects the increasing demand for personalized and precise cancer treatment modalities, as well as the positive outcomes seen in mRNA-based vaccine deployment during the COVID-19 pandemic.
Regionally, North America dominates the market with a valuation of USD 1.68 billion in 2024, expected to grow to USD 10.25 billion by 2032, at a CAGR of 25.3%.
Europe follows with a 28% market share, while Asia-Pacific is projected to witness high growth due to increasing investments in biopharmaceutical R&D.
Market Dynamics (Drivers, Restraints, Opportunities, and Challenges)
Drivers:
-
Increasing incidence of various cancers globally.
-
Rising demand for personalized cancer treatment.
-
Technological advancements in mRNA platforms and LNP formulations.
-
Strong government and private investment in mRNA R&D.
Restraints:
-
High costs associated with mRNA vaccine development and manufacturing.
-
Cold-chain storage and transportation challenges.
-
Regulatory complexities in approving new therapies.
Opportunities:
-
Expansion into emerging markets with untapped potential.
-
Innovations in delivery systems to enhance stability and efficacy.
-
Potential combination therapies with other immunotherapies or checkpoint inhibitors.
Challenges:
-
Scalability of manufacturing to meet global demand.
-
Ensuring long-term safety and effectiveness across diverse populations.
-
Intellectual property disputes and competitive barriers.
Regional Analysis
- North America: Holds the largest share with 69% of the market in 2024. The U.S. leads due to strong biotech infrastructure, government support, and leading players such as Moderna and BioNTech conducting clinical trials in the region.
- Europe: Accounts for 28% of the market. Countries like Germany and the UK are investing heavily in life sciences and oncology research.
- Asia-Pacific: Expected to experience rapid growth with China, India, and Japan increasing healthcare expenditure and mRNA R&D investments.
- Middle East and Africa: Still in early stages but projected to grow with increased awareness and healthcare infrastructure development.
- South and Central America: Shows moderate growth potential with Brazil and Argentina leading in regional biotech initiatives.
Competitor Analysis (in brief)
The mRNA cancer vaccines and therapeutics space is dominated by a few key players. In 2024, the top three companies—Moderna Therapeutics, CureVac, and BioNTech—collectively hold 82% market share. These companies lead due to their proprietary technologies, robust clinical pipelines, and strategic partnerships.
Other notable players include:
-
Translate Bio – known for its research on infectious diseases and expanding into oncology.
-
Sangamo Therapeutics – integrates mRNA with gene editing tools.
-
Argos Therapeutics, In-Cell-Art, eTheRNA, Ethris, Tiba Biotechnology – actively involved in niche applications and innovative delivery platforms.
Global mRNA Cancer Vaccines and Therapeutics Market Segmentation Analysis
This report provides a deep insight into the global mRNA Cancer Vaccines and Therapeutics Market, covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and assessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global mRNA Cancer Vaccines and Therapeutics Market. This report introduces in detail the market share, market performance, product situation, operation situation, etc., of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the mRNA Cancer Vaccines and Therapeutics Market in any manner.
Market Segmentation (by Application)
- Infectious Diseases
- Oncology
- Rare Genetic Diseases
- Others (Respiratory Diseases, etc.)
End-user
- Hospitals & Clinics
- Biopharmaceutical Companies
- Others (Research Organizations,
mRNA Type
- Nucleoside-modified mRNA
- Unmodified mRNA
- Self-amplifying mRNA
Market Segmentation (by Type)
Companies Profiled
- Moderna, Inc.
- BioNTech SE.
- CureVac SE
- Arcturus Therapeutics, Inc.
- Sanofi
- GSK plc
- Argos Therapeutics Inc.
- Ethris
- Pfizer Inc.
- AstraZeneca
- Translate Bio
- Sangamo Therapeutics
- Argos Therapeuticse
- TheRNAEthris
- Tiba Biotechnology
Geographic Segmentation
- North America (United States, Canada, Mexico)
- Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe)
- Asia-Pacific (China, India, Japan, South Korea, Australia, Rest of APAC)
- The Middle East and Africa (Middle East, Africa)
- South and Central America (Brazil, Argentina, Rest of SCA)
FAQ
What is the current market size of the mRNA Cancer Vaccines and Therapeutics Market?
- The market was valued at USD 2.85 billion in 2024 and is projected to reach USD 18.72 billion by 2032.
Which are the key companies operating in the mRNA Cancer Vaccines and Therapeutics Market?
- Moderna Therapeutics, CureVac, Translate Bio, BioNTech, Sangamo Therapeutics, Argos Therapeutics, In-Cell-Art, eTheRNA, Ethris, and Tiba Biotechnology.
What are the key growth drivers in the mRNA Cancer Vaccines and Therapeutics Market?
- Key drivers include rising cancer incidences, demand for personalized treatment, advancements in mRNA technology, and strong funding support.
Which regions dominate the mRNA Cancer Vaccines and Therapeutics Market?
- North America leads with 69% market share, followed by Europe.
What are the emerging trends in the mRNA Cancer Vaccines and Therapeutics Market?
- Emerging trends include individualized cancer vaccines, improved LNP delivery systems, and integration of mRNA platforms with gene editing and immunotherapies.
Outline of Major Chapters:
- Chapter 1: Introduces the definition of mRNA Cancer Vaccines and Therapeutics, market overview.
- Chapter 2: Global mRNA Cancer Vaccines and Therapeutics market size in revenue.
- Chapter 3: Detailed analysis of mRNA Cancer Vaccines and Therapeutics company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
- Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
- Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
- Chapter 6: Sales of mRNA Cancer Vaccines and Therapeutics in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
- Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
- Chapter 8: The main points and conclusions of the report.
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 mRNA Cancer Vaccines and Therapeutics Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global mRNA Cancer Vaccines and Therapeutics Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global mRNA Cancer Vaccines and Therapeutics Overall Market Size
2.1 Global mRNA Cancer Vaccines and Therapeutics Market Size: 2022 VS 2030
2.2 Global mRNA Cancer Vaccines and Therapeutics Market Size, Prospects & Forecasts: 2018-2030
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top mRNA Cancer Vaccines and Therapeutics Players in Global Market
3.2 Top Global mRNA Cancer Vaccines and Therapeutics Companies Ranked by Revenue
3.3 Global mRNA Cancer Vaccines and Therapeutics Revenue by Companies
3.4 Top 3 and Top 5 mRNA Cancer Vaccines and Therapeutics Companies in Global Market, by Revenue in 2022
3.5 Global Companies mRNA Cancer Vaccines and Therapeutics Product Type
3.6 Tier 1, Tier 2 and Tier 3 mRNA Cancer Vaccines and Therapeutics Players in Global Market
3.6.1 List of Global Tier 1 mRNA Cancer Vaccines and Therapeutics Companies
3.6.2 List of Global Tier 2 and Tier 3 mRNA Cancer Vaccines and Therapeutics Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global mRNA Cancer Vaccines and Therapeutics Market Size Markets, 2022 & 2030
4.1.2 Standardization Of Cancer Treatment MRNA Vaccine
4.1.3 Individualized Cancer Treatment MRNA Vaccine
4.1.4 Infectious Disease Treatment MRNA Vaccine
4.1.5 Infection Prevention MRNA Vaccine
4.2 By Type - Global mRNA Cancer Vaccines and Therapeutics Revenue & Forecasts
4.2.1 By Type - Global mRNA Cancer Vaccines and Therapeutics Revenue, 2018-2023
4.2.2 By Type - Global mRNA Cancer Vaccines and Therapeutics Revenue, 2024-2030
4.2.3 By Type - Global mRNA Cancer Vaccines and Therapeutics Revenue Market Share, 2018-2030
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global mRNA Cancer Vaccines and Therapeutics Market Size, 2022 & 2030
5.1.2 Infectious Disease
5.1.3 Cancer
5.1.4 Other
5.2 By Application - Global mRNA Cancer Vaccines and Therapeutics Revenue & Forecasts
5.2.1 By Application - Global mRNA Cancer Vaccines and Therapeutics Revenue, 2018-2023
5.2.2 By Application - Global mRNA Cancer Vaccines and Therapeutics Revenue, 2024-2030
5.2.3 By Application - Global mRNA Cancer Vaccines and Therapeutics Revenue Market Share, 2018-2030
6 Sights by Region
6.1 By Region - Global mRNA Cancer Vaccines and Therapeutics Market Size, 2022 & 2030
6.2 By Region - Global mRNA Cancer Vaccines and Therapeutics Revenue & Forecasts
6.2.1 By Region - Global mRNA Cancer Vaccines and Therapeutics Revenue, 2018-2023
6.2.2 By Region - Global mRNA Cancer Vaccines and Therapeutics Revenue, 2024-2030
6.2.3 By Region - Global mRNA Cancer Vaccines and Therapeutics Revenue Market Share, 2018-2030
6.3 North America
6.3.1 By Country - North America mRNA Cancer Vaccines and Therapeutics Revenue, 2018-2030
6.3.2 US mRNA Cancer Vaccines and Therapeutics Market Size, 2018-2030
6.3.3 Canada mRNA Cancer Vaccines and Therapeutics Market Size, 2018-2030
6.3.4 Mexico mRNA Cancer Vaccines and Therapeutics Market Size, 2018-2030
6.4 Europe
6.4.1 By Country - Europe mRNA Cancer Vaccines and Therapeutics Revenue, 2018-2030
6.4.2 Germany mRNA Cancer Vaccines and Therapeutics Market Size, 2018-2030
6.4.3 France mRNA Cancer Vaccines and Therapeutics Market Size, 2018-2030
6.4.4 U.K. mRNA Cancer Vaccines and Therapeutics Market Size, 2018-2030
6.4.5 Italy mRNA Cancer Vaccines and Therapeutics Market Size, 2018-2030
6.4.6 Russia mRNA Cancer Vaccines and Therapeutics Market Size, 2018-2030
6.4.7 Nordic Countries mRNA Cancer Vaccines and Therapeutics Market Size, 2018-2030
6.4.8 Benelux mRNA Cancer Vaccines and Therapeutics Market Size, 2018-2030
6.5 Asia
6.5.1 By Region - Asia mRNA Cancer Vaccines and Therapeutics Revenue, 2018-2030
6.5.2 China mRNA Cancer Vaccines and Therapeutics Market Size, 2018-2030
6.5.3 Japan mRNA Cancer Vaccines and Therapeutics Market Size, 2018-2030
6.5.4 South Korea mRNA Cancer Vaccines and Therapeutics Market Size, 2018-2030
6.5.5 Southeast Asia mRNA Cancer Vaccines and Therapeutics Market Size, 2018-2030
6.5.6 India mRNA Cancer Vaccines and Therapeutics Market Size, 2018-2030
6.6 South America
6.6.1 By Country - South America mRNA Cancer Vaccines and Therapeutics Revenue, 2018-2030
6.6.2 Brazil mRNA Cancer Vaccines and Therapeutics Market Size, 2018-2030
6.6.3 Argentina mRNA Cancer Vaccines and Therapeutics Market Size, 2018-2030
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa mRNA Cancer Vaccines and Therapeutics Revenue, 2018-2030
6.7.2 Turkey mRNA Cancer Vaccines and Therapeutics Market Size, 2018-2030
6.7.3 Israel mRNA Cancer Vaccines and Therapeutics Market Size, 2018-2030
6.7.4 Saudi Arabia mRNA Cancer Vaccines and Therapeutics Market Size, 2018-2030
6.7.5 UAE mRNA Cancer Vaccines and Therapeutics Market Size, 2018-2030
7 mRNA Cancer Vaccines and Therapeutics Companies Profiles
7.1 Moderna Therapeutics
7.1.1 Moderna Therapeutics Company Summary
7.1.2 Moderna Therapeutics Business Overview
7.1.3 Moderna Therapeutics mRNA Cancer Vaccines and Therapeutics Major Product Offerings
7.1.4 Moderna Therapeutics mRNA Cancer Vaccines and Therapeutics Revenue in Global Market (2018-2023)
7.1.5 Moderna Therapeutics Key News & Latest Developments
7.2 CureVac
7.2.1 CureVac Company Summary
7.2.2 CureVac Business Overview
7.2.3 CureVac mRNA Cancer Vaccines and Therapeutics Major Product Offerings
7.2.4 CureVac mRNA Cancer Vaccines and Therapeutics Revenue in Global Market (2018-2023)
7.2.5 CureVac Key News & Latest Developments
7.3 Translate Bio
7.3.1 Translate Bio Company Summary
7.3.2 Translate Bio Business Overview
7.3.3 Translate Bio mRNA Cancer Vaccines and Therapeutics Major Product Offerings
7.3.4 Translate Bio mRNA Cancer Vaccines and Therapeutics Revenue in Global Market (2018-2023)
7.3.5 Translate Bio Key News & Latest Developments
7.4 BioNTech
7.4.1 BioNTech Company Summary
7.4.2 BioNTech Business Overview
7.4.3 BioNTech mRNA Cancer Vaccines and Therapeutics Major Product Offerings
7.4.4 BioNTech mRNA Cancer Vaccines and Therapeutics Revenue in Global Market (2018-2023)
7.4.5 BioNTech Key News & Latest Developments
7.5 Sangamo Therapeutics
7.5.1 Sangamo Therapeutics Company Summary
7.5.2 Sangamo Therapeutics Business Overview
7.5.3 Sangamo Therapeutics mRNA Cancer Vaccines and Therapeutics Major Product Offerings
7.5.4 Sangamo Therapeutics mRNA Cancer Vaccines and Therapeutics Revenue in Global Market (2018-2023)
7.5.5 Sangamo Therapeutics Key News & Latest Developments
7.6 Argos Therapeutics
7.6.1 Argos Therapeutics Company Summary
7.6.2 Argos Therapeutics Business Overview
7.6.3 Argos Therapeutics mRNA Cancer Vaccines and Therapeutics Major Product Offerings
7.6.4 Argos Therapeutics mRNA Cancer Vaccines and Therapeutics Revenue in Global Market (2018-2023)
7.6.5 Argos Therapeutics Key News & Latest Developments
7.7 In-Cell-Art
7.7.1 In-Cell-Art Company Summary
7.7.2 In-Cell-Art Business Overview
7.7.3 In-Cell-Art mRNA Cancer Vaccines and Therapeutics Major Product Offerings
7.7.4 In-Cell-Art mRNA Cancer Vaccines and Therapeutics Revenue in Global Market (2018-2023)
7.7.5 In-Cell-Art Key News & Latest Developments
7.8 eTheRNA
7.8.1 eTheRNA Company Summary
7.8.2 eTheRNA Business Overview
7.8.3 eTheRNA mRNA Cancer Vaccines and Therapeutics Major Product Offerings
7.8.4 eTheRNA mRNA Cancer Vaccines and Therapeutics Revenue in Global Market (2018-2023)
7.8.5 eTheRNA Key News & Latest Developments
7.9 Ethris
7.9.1 Ethris Company Summary
7.9.2 Ethris Business Overview
7.9.3 Ethris mRNA Cancer Vaccines and Therapeutics Major Product Offerings
7.9.4 Ethris mRNA Cancer Vaccines and Therapeutics Revenue in Global Market (2018-2023)
7.9.5 Ethris Key News & Latest Developments
7.10 Tiba Biotechnology
7.10.1 Tiba Biotechnology Company Summary
7.10.2 Tiba Biotechnology Business Overview
7.10.3 Tiba Biotechnology mRNA Cancer Vaccines and Therapeutics Major Product Offerings
7.10.4 Tiba Biotechnology mRNA Cancer Vaccines and Therapeutics Revenue in Global Market (2018-2023)
7.10.5 Tiba Biotechnology Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. mRNA Cancer Vaccines and Therapeutics Market Opportunities & Trends in Global Market
Table 2. mRNA Cancer Vaccines and Therapeutics Market Drivers in Global Market
Table 3. mRNA Cancer Vaccines and Therapeutics Market Restraints in Global Market
Table 4. Key Players of mRNA Cancer Vaccines and Therapeutics in Global Market
Table 5. Top mRNA Cancer Vaccines and Therapeutics Players in Global Market, Ranking by Revenue (2022)
Table 6. Global mRNA Cancer Vaccines and Therapeutics Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global mRNA Cancer Vaccines and Therapeutics Revenue Share by Companies, 2018-2023
Table 8. Global Companies mRNA Cancer Vaccines and Therapeutics Product Type
Table 9. List of Global Tier 1 mRNA Cancer Vaccines and Therapeutics Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 mRNA Cancer Vaccines and Therapeutics Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global mRNA Cancer Vaccines and Therapeutics Revenue, (US$, Mn), 2022 & 2030
Table 12. By Type - mRNA Cancer Vaccines and Therapeutics Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - mRNA Cancer Vaccines and Therapeutics Revenue in Global (US$, Mn), 2024-2030
Table 14. By Application ? Global mRNA Cancer Vaccines and Therapeutics Revenue, (US$, Mn), 2022 & 2030
Table 15. By Application - mRNA Cancer Vaccines and Therapeutics Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - mRNA Cancer Vaccines and Therapeutics Revenue in Global (US$, Mn), 2024-2030
Table 17. By Region ? Global mRNA Cancer Vaccines and Therapeutics Revenue, (US$, Mn), 2022 & 2030
Table 18. By Region - Global mRNA Cancer Vaccines and Therapeutics Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global mRNA Cancer Vaccines and Therapeutics Revenue (US$, Mn), 2024-2030
Table 20. By Country - North America mRNA Cancer Vaccines and Therapeutics Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America mRNA Cancer Vaccines and Therapeutics Revenue, (US$, Mn), 2024-2030
Table 22. By Country - Europe mRNA Cancer Vaccines and Therapeutics Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe mRNA Cancer Vaccines and Therapeutics Revenue, (US$, Mn), 2024-2030
Table 24. By Region - Asia mRNA Cancer Vaccines and Therapeutics Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia mRNA Cancer Vaccines and Therapeutics Revenue, (US$, Mn), 2024-2030
Table 26. By Country - South America mRNA Cancer Vaccines and Therapeutics Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America mRNA Cancer Vaccines and Therapeutics Revenue, (US$, Mn), 2024-2030
Table 28. By Country - Middle East & Africa mRNA Cancer Vaccines and Therapeutics Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa mRNA Cancer Vaccines and Therapeutics Revenue, (US$, Mn), 2024-2030
Table 30. Moderna Therapeutics Company Summary
Table 31. Moderna Therapeutics mRNA Cancer Vaccines and Therapeutics Product Offerings
Table 32. Moderna Therapeutics mRNA Cancer Vaccines and Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 33. Moderna Therapeutics Key News & Latest Developments
Table 34. CureVac Company Summary
Table 35. CureVac mRNA Cancer Vaccines and Therapeutics Product Offerings
Table 36. CureVac mRNA Cancer Vaccines and Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 37. CureVac Key News & Latest Developments
Table 38. Translate Bio Company Summary
Table 39. Translate Bio mRNA Cancer Vaccines and Therapeutics Product Offerings
Table 40. Translate Bio mRNA Cancer Vaccines and Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 41. Translate Bio Key News & Latest Developments
Table 42. BioNTech Company Summary
Table 43. BioNTech mRNA Cancer Vaccines and Therapeutics Product Offerings
Table 44. BioNTech mRNA Cancer Vaccines and Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 45. BioNTech Key News & Latest Developments
Table 46. Sangamo Therapeutics Company Summary
Table 47. Sangamo Therapeutics mRNA Cancer Vaccines and Therapeutics Product Offerings
Table 48. Sangamo Therapeutics mRNA Cancer Vaccines and Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 49. Sangamo Therapeutics Key News & Latest Developments
Table 50. Argos Therapeutics Company Summary
Table 51. Argos Therapeutics mRNA Cancer Vaccines and Therapeutics Product Offerings
Table 52. Argos Therapeutics mRNA Cancer Vaccines and Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 53. Argos Therapeutics Key News & Latest Developments
Table 54. In-Cell-Art Company Summary
Table 55. In-Cell-Art mRNA Cancer Vaccines and Therapeutics Product Offerings
Table 56. In-Cell-Art mRNA Cancer Vaccines and Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 57. In-Cell-Art Key News & Latest Developments
Table 58. eTheRNA Company Summary
Table 59. eTheRNA mRNA Cancer Vaccines and Therapeutics Product Offerings
Table 60. eTheRNA mRNA Cancer Vaccines and Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 61. eTheRNA Key News & Latest Developments
Table 62. Ethris Company Summary
Table 63. Ethris mRNA Cancer Vaccines and Therapeutics Product Offerings
Table 64. Ethris mRNA Cancer Vaccines and Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 65. Ethris Key News & Latest Developments
Table 66. Tiba Biotechnology Company Summary
Table 67. Tiba Biotechnology mRNA Cancer Vaccines and Therapeutics Product Offerings
Table 68. Tiba Biotechnology mRNA Cancer Vaccines and Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 69. Tiba Biotechnology Key News & Latest Developments
List of Figures
Figure 1. mRNA Cancer Vaccines and Therapeutics Segment by Type in 2022
Figure 2. mRNA Cancer Vaccines and Therapeutics Segment by Application in 2022
Figure 3. Global mRNA Cancer Vaccines and Therapeutics Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global mRNA Cancer Vaccines and Therapeutics Market Size: 2022 VS 2030 (US$, Mn)
Figure 6. Global mRNA Cancer Vaccines and Therapeutics Revenue, 2018-2030 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by mRNA Cancer Vaccines and Therapeutics Revenue in 2022
Figure 8. By Type - Global mRNA Cancer Vaccines and Therapeutics Revenue Market Share, 2018-2030
Figure 9. By Application - Global mRNA Cancer Vaccines and Therapeutics Revenue Market Share, 2018-2030
Figure 10. By Type - Global mRNA Cancer Vaccines and Therapeutics Revenue, (US$, Mn), 2022 & 2030
Figure 11. By Type - Global mRNA Cancer Vaccines and Therapeutics Revenue Market Share, 2018-2030
Figure 12. By Application - Global mRNA Cancer Vaccines and Therapeutics Revenue, (US$, Mn), 2022 & 2030
Figure 13. By Application - Global mRNA Cancer Vaccines and Therapeutics Revenue Market Share, 2018-2030
Figure 14. By Region - Global mRNA Cancer Vaccines and Therapeutics Revenue Market Share, 2018-2030
Figure 15. By Country - North America mRNA Cancer Vaccines and Therapeutics Revenue Market Share, 2018-2030
Figure 16. US mRNA Cancer Vaccines and Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 17. Canada mRNA Cancer Vaccines and Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 18. Mexico mRNA Cancer Vaccines and Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 19. By Country - Europe mRNA Cancer Vaccines and Therapeutics Revenue Market Share, 2018-2030
Figure 20. Germany mRNA Cancer Vaccines and Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 21. France mRNA Cancer Vaccines and Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 22. U.K. mRNA Cancer Vaccines and Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 23. Italy mRNA Cancer Vaccines and Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 24. Russia mRNA Cancer Vaccines and Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 25. Nordic Countries mRNA Cancer Vaccines and Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 26. Benelux mRNA Cancer Vaccines and Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 27. By Region - Asia mRNA Cancer Vaccines and Therapeutics Revenue Market Share, 2018-2030
Figure 28. China mRNA Cancer Vaccines and Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 29. Japan mRNA Cancer Vaccines and Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 30. South Korea mRNA Cancer Vaccines and Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 31. Southeast Asia mRNA Cancer Vaccines and Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 32. India mRNA Cancer Vaccines and Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 33. By Country - South America mRNA Cancer Vaccines and Therapeutics Revenue Market Share, 2018-2030
Figure 34. Brazil mRNA Cancer Vaccines and Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 35. Argentina mRNA Cancer Vaccines and Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 36. By Country - Middle East & Africa mRNA Cancer Vaccines and Therapeutics Revenue Market Share, 2018-2030
Figure 37. Turkey mRNA Cancer Vaccines and Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 38. Israel mRNA Cancer Vaccines and Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 39. Saudi Arabia mRNA Cancer Vaccines and Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 40. UAE mRNA Cancer Vaccines and Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 41. Moderna Therapeutics mRNA Cancer Vaccines and Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. CureVac mRNA Cancer Vaccines and Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. Translate Bio mRNA Cancer Vaccines and Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. BioNTech mRNA Cancer Vaccines and Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. Sangamo Therapeutics mRNA Cancer Vaccines and Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. Argos Therapeutics mRNA Cancer Vaccines and Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. In-Cell-Art mRNA Cancer Vaccines and Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 48. eTheRNA mRNA Cancer Vaccines and Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 49. Ethris mRNA Cancer Vaccines and Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 50. Tiba Biotechnology mRNA Cancer Vaccines and Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
